menu search

TNDM / Tandem Diabetes Care, Inc. (TNDM) CEO John Sheridan on Q2 2022 Results - Earnings Call Transcript

Tandem Diabetes Care, Inc. (TNDM) CEO John Sheridan on Q2 2022 Results - Earnings Call Transcript
Tandem Diabetes Care, Inc. (NASDAQ:TNDM ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Susan Morrison - Executive VP & Chief Administrative Officer John Sheridan - President, CEO & Director Brian Hansen - EVP & Chief Commercial Officer Leigh Vosseller - EVP, CFO & Treasurer Conference Call Participants Steven Lichtman - Oppenheimer Brooks O'Neil - Lake Street Capital Markets Travis Steed - Bank of America Merrill Lynch Jayson Bedford - Raymond James & Associates Matthew O'Brien - Piper Sandler & Co. Christopher Pasquale - Nephron Research Dane Reinhardt - Robert W. Baird & Co. Operator Thank you for standing by, and welcome to Tandem's Second Quarter 2022 Earnings Conference Call. Read More
Posted: Aug 3 2022, 23:02
Author Name: Seeking Alpha
Views: 092118

TNDM News  

Tandem Diabetes Care, Inc. (TNDM) Q3 2023 Earnings Call Transcript

By Seeking Alpha
November 1, 2023

Tandem Diabetes Care, Inc. (TNDM) Q3 2023 Earnings Call Transcript

Tandem Diabetes Care, Inc. (NASDAQ:TNDM ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Susan Morrison - EVP & Chi more_horizontal

Compared to Estimates, Tandem Diabetes Care, Inc. (TNDM) Q3 Earnings: A Look at Key Metrics

By Zacks Investment Research
November 1, 2023

Compared to Estimates, Tandem Diabetes Care, Inc. (TNDM) Q3 Earnings: A Look at Key Metrics

Although the revenue and EPS for Tandem Diabetes Care, Inc. (TNDM) give a sense of how its business performed in the quarter ended September 2023, it more_horizontal

Tandem Diabetes Care, Inc. (TNDM) Soars 6.0%: Is Further Upside Left in the Stock?

By Zacks Investment Research
October 16, 2023

Tandem Diabetes Care, Inc. (TNDM) Soars 6.0%: Is Further Upside Left in the Stock?

Tandem Diabetes Care, Inc. (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions more_horizontal

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

By Zacks Investment Research
October 9, 2023

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

Investors remain optimistic about Tandem Diabetes (TNDM), backed by strategic developments and innovative new launches. more_horizontal

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

By Zacks Investment Research
August 25, 2023

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

Investors continue to be optimistic about Tandem Diabetes (TNDM) due to the t:slim X2 insulin pump and new product innovations. more_horizontal

Tandem Diabetes (TNDM) Reports Narrower Q2 Loss, Trims '23 View

By Zacks Investment Research
August 4, 2023

Tandem Diabetes (TNDM) Reports Narrower Q2 Loss, Trims '23 View

Tandem Diabetes' (TNDM) second-quarter 2023 performance reflects new technology innovations and operational improvements throughout its business. more_horizontal

Compared to Estimates, Tandem Diabetes Care, Inc. (TNDM) Q2 Earnings: A Look at Key Metrics

By Zacks Investment Research
August 3, 2023

Compared to Estimates, Tandem Diabetes Care, Inc. (TNDM) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for Tandem Diabetes Care, Inc. (TNDM) give a sense of how its business performed in the quarter ended June 2023, it might more_horizontal

Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Lags Revenue Estimates

By Zacks Investment Research
August 3, 2023

Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Lags Revenue Estimates

Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compa more_horizontal


Search within

Pages Search Results: